ZFIN Image: Cho et al., 2023, Figure 9

Image

Figure Caption

Figure 9

Comparison of the swimming ability and survivability after an intraperitoneal injection of carboxymethyllysine (CML) with Infliximab (Remsima), Etanercept (Enbrel), Tocilizumab (Actemra), or CIGB-258 (Jusvinza). (A) Still image of the swimming pattern of zebrafish 30 min and 120 min post-injection of CML with Infliximab (Remsima), Etanercept (Enbrel), Tocilizumab (Actemra), or CIGB-258 (Jusvinza) 30 min and 120 min post-injection. (B) Survivability of the zebrafish at 180 min post-injection of CML with Infliximab (Remsima), Etanercept (Enbrel), Tocilizumab (Actemra), or CIGB-258 (Jusvinza). *, p < 0.05 versus CML + PBS; ***, p < 0.001 versus CML + PBS. (C) Percentage of swimming zebrafish after an injection of CML with Infliximab (Remsima), Etanercept (Enbrel), Tocilizumab (Actemra), or CIGB-258 (Jusvinza) at 30 min, 60 min, and 120 min post-injection. *, p < 0.05 versus CML + PBS; ***, p < 0.001 versus CML + PBS.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Int. J. Mol. Sci.